Insider buying
~$82K1,000 sh @ $81.81
Traded Apr 8, 2025 · filed 6 days later
The CFO of Nutex Health paid $82K out of pocket for Nutex Health shares. Shares held went up 26% with this purchase.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
NUTX · NASDAQ · Services-Business Services, Nec
Nutex Health (NUTX) · oqro.io/stocks/NUTX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$162.64+0.54 (+0.33%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Insider buying
Traded Apr 8, 2025 · filed 6 days later
The CFO of Nutex Health paid $82K out of pocket for Nutex Health shares. Shares held went up 26% with this purchase.
0 open-market purchases and 0 open-market sales by insiders of NUTX between Feb 3, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 5, 2026. The data provider lists the next release for Mar 3, 2027; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Nov 5, 2026 | None | None | None |
| Aug 6, 2026 | None | None | None |
| Apr 30, 2026 | None | None | None |
| Mar 5, 2026 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies